Status:

COMPLETED

Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients

Lead Sponsor:

Azienda Ospedaliera San Giovanni Battista

Collaborating Sponsors:

University of Turin, Italy

Conditions:

Genital Diseases, Female

Ovarian Neoplasms

Eligibility:

FEMALE

18+ years

Brief Summary

The purpose of this study is to determine whether HGF serum concentration might be raised in vivo by administering nadroparin given with prophylactic purpose to gynecological patients.

Detailed Description

The study consisted of two phases. In the first phase, the main HGF pharmacokinetic parameters were evaluated, comparing a group of six women treated with a single dose of calcic nadroparin to a contr...

Eligibility Criteria

Inclusion

  • ≥ 18 years
  • ECOG PS ≤ 1
  • Neutrophils ≥ 1500 l -1, platelets ≥ 150,000 l -1, creatinine 0.6 to 1.2 mg dl -1, total bilirubin ≤ 1 mg dL -1, AST ≤ 35 U l-1, ALT ≤ 45 U l-1
  • For patients in the study group: high-moderate risk of deep vein thrombosis (for the administration of LMWH for 30 days after surgery) under general anesthesia\> 30 minutes, laparoscopy + at least one risk factor (age\> 40 years, obesity, varicose veins, previous episode of deep vein thrombosis and / or pulmonary thromboembolism, thrombophilia, malignancy, prolonged immobility, congestive heart failure)

Exclusion

  • severe liver and renal disease
  • diabetes
  • hyperlipidemia
  • marked osteoporosis
  • HIV infection
  • ongoing treatment with: immunosuppressive therapies, contraceptives, lipid-lowering drugs, NSAIDs, antiplatelet drugs, recent acute inflammatory or infectious (\<3 weeks)
  • a history of allergies,
  • drug possible confounding, caffeine, tobacco, ethanol (must not have been hired in the last 24 hours prior to sampling)
  • high risk of bleeding: peptic ulcer, history of hemorrhagic stroke, or bleeding disorders, severe hypertension, cerebral aneurysms, arteriovenous malformations, brain metastases

Key Trial Info

Start Date :

November 1 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 1 2008

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT01523652

Start Date

November 1 2007

End Date

November 1 2008

Last Update

February 1 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ASO Ordine Mauriziano

Turin, Italy